Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COPIKTRA vs TENUATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies,Relapsed or refractory follicular lymphoma after at least two prior systemic therapies
FDA-approved: short-term (up to 12 weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with exogenous obesity.,Off-label: long-term management of obesity (not FDA-approved for extended use).
25 mg orally twice daily
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
Terminal elimination half-life is approximately 7–10 hours in patients with relapsed or refractory CLL/SLL. Steady-state is achieved within 3–5 days of twice-daily dosing.
4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing
Primarily metabolized by CYP3A4; also involves CYP3A5 and UDP-glucuronosyltransferases (UGTs).
Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6.
Primarily via fecal excretion (approximately 70% of total dose) as unchanged drug and metabolites, with renal excretion accounting for <15% of the dose.
Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%)
~84% bound to plasma proteins, primarily to albumin.
~92% (primarily albumin)
Mean apparent volume of distribution (Vz/F) is approximately 100–150 L (or ~1.4–2.1 L/kg based on typical body weight), indicating extensive tissue distribution.
~4 L/kg (extensive tissue distribution, including CNS)
Oral bioavailability is approximately 22% following a 25 mg capsule under fasting conditions. Absorption is increased with high-fat meals; therefore, it should be taken on an empty stomach.
Oral: ~60-70% (first-pass metabolism)
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min).
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild (Child-Pugh class A) or moderate (Child-Pugh class B), reduce dose to 25 mg once daily.
Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction.
Safety and efficacy in pediatric patients have not been established.
Not recommended for children under 16 years of age.
No specific dose adjustment recommended for elderly patients, but monitor for adverse effects due to potential age-related renal or hepatic impairment.
Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects.
WARNING: FATAL AND SERIOUS TOXICITIES: Fatal and serious toxicities including infections, diarrhea or colitis, cutaneous reactions, and pneumonitis have occurred with COPIKTRA.
There is no FDA boxed warning for Tenuate.
Fatal and serious infections,Fatal and serious diarrhea or colitis,Fatal and serious cutaneous reactions,Fatal and serious pneumonitis,Neutropenia,Hepatotoxicity,Embryo-fetal toxicity
Primary pulmonary hypertension: rare but serious condition associated with use.,Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs.,Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks.,Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse.,Seizures: risk increased in patients with epilepsy or history of seizures.
Concurrent use with strong CYP3A inhibitors due to increased toxicity risk
Hypersensitivity to diethylpropion or other sympathomimetic amines.,Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.,History of drug abuse, agitated states.,Concurrent use (or within 14 days of discontinuing) MAO inhibitors (hypertensive crisis risk).
Avoid grapefruit and grapefruit juice; may increase dupilumab exposure. Take with or without food.
Avoid caffeine and other stimulants (e.g., in coffee, tea, cola, energy drinks) as they may increase cardiovascular side effects. Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if also taking MAOIs, but this is relevant only if transitioning therapy. No specific food restrictions otherwise, but a reduced-calorie diet is essential for efficacy.
COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studies, duvelisib was embryotoxic and fetotoxic at maternal exposures below the recommended human dose. There are no adequate human data. Risks include embryo-fetal mortality, structural abnormalities, and growth impairment across all trimesters.
First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed.
No data on duvelisib presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., immunosuppression, neutropenia), advise women not to breastfeed during treatment and for at least 1 month after last dose. M/P ratio unknown.
Excreted in human milk; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., irritability, poor weight gain). Use caution; decision to discontinue nursing or drug based on importance to mother.
No pharmacokinetic studies have been conducted in pregnant women. No dosing adjustments are recommended because duvelisib is contraindicated in pregnancy. If used inadvertently, the standard dose (25 mg twice daily) should be maintained until drug discontinuation is considered.
No specific pharmacokinetic data; however, pregnancy may alter metabolism. Start with lowest effective dose (25 mg BID) and monitor clinical response. Avoid sustained-release formulations due to altered GI transit.
Monitor for hepatotoxicity with baseline and periodic liver function tests; avoid live vaccines; consider dose reduction in patients with moderate hepatic impairment (Child-Pugh B); watch for infections due to neutropenia; contraindicated in severe hepatic impairment (Child-Pugh C).
Tenuate (diethylpropion) is a sympathomimetic amine anorectic indicated for short-term (8-12 weeks) adjunct in obesity management. Avoid in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, or glaucoma. Monitor blood pressure and heart rate regularly. Tolerance may develop; discontinue if tolerance occurs. Contraindicated with MAOIs or within 14 days of their use. May impair ability to drive or operate machinery.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection (fever, chills, cough) or jaundice (yellowing skin/eyes) immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not receive live vaccines during or shortly after treatment.
Take exactly as prescribed; do not increase dose or duration.,May cause dizziness or blurred vision; avoid driving if affected.,Inform your doctor if you have heart disease, high blood pressure, or thyroid problems.,Avoid alcohol and other CNS stimulants while taking this medication.,Report any chest pain, palpitations, or severe headache immediately.,Do not take with other appetite suppressants without consulting your doctor.,This medication is only for short-term use; combine with diet and exercise.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COPIKTRA vs TENUATE, answered by our medical review team.
COPIKTRA is a PI3K Inhibitor Antineoplastic that works by Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.. TENUATE is a Sympathomimetic anorectic that works by Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COPIKTRA and TENUATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COPIKTRA is: 25 mg orally twice daily. The standard adult dose of TENUATE is: 25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COPIKTRA and TENUATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COPIKTRA is classified as Category C. COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studi. TENUATE is classified as Category C. First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.